Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Talazoparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 15/20 | 1.00 |
| ▸ | PARP3 | Q9Y6F1 | 15/20 | 1.00 |
| ▸ | TNKS | O95271 | 2/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 1.00 |
| ▸ | PARP16 | Q8N5Y8 | 2/20 | 1.00 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 1.00 |
| ▸ | PARP15 | Q460N3 | 1/20 | 1.00 |
| ▸ | PARP14 | Q460N5 | 1/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 1.00 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 1.00 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talazoparib SCHEMBL30099172 | 1.00 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 | |
| Talazoparib SCHEMBL16204525 | 1.00 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 | |
| Talazoparib SCHEMBL30099170 | 1.00 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 | |
| Talazoparib SCHEMBL23048317 | 1.00 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 | |
| Talazoparib SCHEMBL2046086 | 1.00 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 | |
| Talazoparib SCHEMBL24440571 | 1.00 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 | |
| Talazoparib SCHEMBL2295997 | 1.00 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 | |
| Talazoparib SCHEMBL30419102 | 1.00 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 | |
| Talazoparib SCHEMBL30953898 | 1.00 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 | |
| Talazoparib SCHEMBL29948077 | 1.00 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380302-A1 | HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASES | NIKANG THERAPEUTICS, INC. | 2022-12-01 | — | — | US | claimed |
| US-11364241-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | MEDIVATION TECHNOLOGIES LLC (US) | 2022-06-21 | — | — | US | claimed |
| US-20210069191-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MEDIVATION TECHNOLOGIES LLC | 2021-03-11 | — | — | US | claimed |
| CN-112334133-A | Quinolone analogs and salts thereof, compositions, and methods of use thereof | 生华生物科技股份有限公司 | 2021-02-05 | — | — | CN | claimed |
| EP-3757106-A1 | CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE TOSYLATE SALT | Medivation Technologies LLC (US) | 2020-12-30 | — | — | EP | claimed |
| US-10780088-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | MEDIVATION TECHNOLOGIES LLC (US) | 2020-09-22 | — | — | US | claimed |
| US-20200261454-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MEDIVATION TECHNOLOGIES LLC | 2020-08-20 | — | — | US | claimed |
| EP-2630146-B1 | CRYSTALINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE TOSYLATE SALT | MEDIVATION TECH LLC (US) | 2020-07-01 | — | — | EP | claimed |
| WO-2019168688-A9 | QUINOLONE ANALOGS AND THEIR SALTS, COMPOSITIONS, AND METHOD FOR THEIR USE | SENHWA BIOSCIENCES, INC. (TW) | 2019-11-14 | — | — | WO | claimed |
| US-20190247371-A1 | METHODS FOR TREATING SMALL CELL LUNG CANCERS BY USING PHARMACEUTICAL COMPOSITIONS OR COMBINATIONS COMPRISING INDOLIZINO[6,7-B]INDOLE DERIVATIVES | ACADEMIA SINICA (TW) | 2019-08-15 | — | — | US | claimed |
| EP-2326650-B9 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARM INC (US) | 2014-09-10 | — | — | EP | claimed |
| EP-2767537-A1 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | BioMarin Pharmaceutical Inc. (US) | 2014-08-20 | — | — | EP | claimed |
| US-20140228369-A1 | CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT | BIOMARIN PHARMACEUTICAL INC. (US) | 2014-08-14 | — | — | US | claimed |
| US-8735392-B2 | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt | BIOMARIN PHARMACEUTICAL INC. (US) | 2014-05-27 | — | — | US | claimed |
| EP-2326650-B1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARM INC (US) | 2014-02-26 | — | — | EP | claimed |
| US-8541403-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency | BIOMARIN PHARMACEUTICAL INC. (US) | 2013-09-24 | — | — | US | claimed |
| US-20120129865-A1 | CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-05-24 | — | — | US | claimed |
| US-8012976-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-09-06 | — | — | US | claimed |
| US-20110190288-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | MEDIVATION TECHNOLOGIES LLC | 2011-08-04 | — | — | US | claimed |
| US-20100035883-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2010-02-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780088-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
| US-11364241-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
| US-20110190288-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 9/4885 |
| US-20140228369-A1 | CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT | CA9, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PARP1 2854/4885PARP2 3798/4885PARP3 4512/4885 |
| US-20100035883-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
| US-20190247371-A1 | METHODS FOR TREATING SMALL CELL LUNG CANCERS BY USING PHARMACEUTICAL COMPOSITIONS OR COMBINATIONS COMPRISING INDOLIZINO[6,7-B]INDOLE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RB1, INMT | PARP1 730/4885PARP2 664/4885PARP3 711/4885 |
| US-20200261454-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
| US-20120129865-A1 | CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT | CA9, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PARP1 2854/4885PARP2 3798/4885PARP3 4512/4885 |
| US-20220380302-A1 | HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASES | HIF1AN, HIF1A, PARP2 | PARP1 6/4885PARP2 3/4885PARP3 9/4885 |
| US-20210069191-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.